These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9279888)

  • 1. Circulatory concentrations of fibrinolytic species during thrombolytic therapy estimated by stirred-tank reactor analysis.
    Tuliani VV; O'Rear EA
    Pharm Res; 1997 Aug; 14(8):1051-7. PubMed ID: 9279888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for the progressive uptake of anisoylated plasminogen streptokinase activator complex by clots in human plasma in vitro.
    Fears R; Ferres H; Standring R
    Drugs; 1987; 33 Suppl 3():51-6. PubMed ID: 2960513
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of anisoylated plasminogen-streptokinase activator complex from the acyl enzyme concept.
    Fears R
    Semin Thromb Hemost; 1989 Apr; 15(2):129-39. PubMed ID: 2665083
    [No Abstract]   [Full Text] [Related]  

  • 4. Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.
    Ferres H
    Drugs; 1987; 33 Suppl 3():33-50. PubMed ID: 3315613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of thrombolytic therapy.
    Lijnen HR; Collen D
    Haemostasis; 1986; 16 Suppl 3():3-15. PubMed ID: 2945766
    [No Abstract]   [Full Text] [Related]  

  • 6. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.
    Collen D; Van Hoef B; Schlott B; Hartmann M; Gührs KH; Lijnen HR
    Eur J Biochem; 1993 Aug; 216(1):307-14. PubMed ID: 7689966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolytic agents and their effects on the haemostatic system.
    Kluft C
    Klin Wochenschr; 1988; 66 Suppl 12():50-4. PubMed ID: 2964542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?
    Collen D; Lijnen HR
    Blood; 1994 Aug; 84(3):680-6. PubMed ID: 7519069
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacology of anistreplase.
    Sherry S
    Clin Cardiol; 1990 Mar; Suppl 5():V3-10; discussion V27-32. PubMed ID: 2182238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
    Crabbe SJ; Grimm AM; Hopkins LE
    Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis.
    Marder VJ; Francis CW
    Prog Hemost Thromb; 1984; 7():325-56. PubMed ID: 6241729
    [No Abstract]   [Full Text] [Related]  

  • 13. The protective effect of acylation on the stability of anisoylated plasminogen streptokinase activator complex in human plasma.
    Fears R; Ferres H; Standring R
    Drugs; 1987; 33 Suppl 3():57-63. PubMed ID: 2960514
    [No Abstract]   [Full Text] [Related]  

  • 14. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of in vitro fibrinogenolysis during laboratory monitoring of thrombolytic therapy with streptokinase or APSAC.
    Hoffmann JJ; Vijgen M
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):279-84. PubMed ID: 1716481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current situation and developmental trends in the field of thrombolytic agents].
    Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1974; 101(1):5-8. PubMed ID: 4134480
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative effects of PEG-containing liposomal formulations on in vivo pharmacokinetics of streptokinase.
    Jin SE; Kim IS; Kim CK
    Arch Pharm Res; 2015 Oct; 38(10):1822-9. PubMed ID: 25851624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha 2-Antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy.
    Collen D; Verstraete M
    Thromb Res; 1979; 14(4-5):631-9. PubMed ID: 90396
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.
    Nagai N; Vanlinthout I; Collen D
    Circulation; 1999 Dec 21-28; 100(25):2541-6. PubMed ID: 10604893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concepts of clot lysis.
    Francis CW; Marder VJ
    Annu Rev Med; 1986; 37():187-204. PubMed ID: 2939790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.